Only a handful of US research labs have the ability to make cancer immunotherapies, called CAR T-cell therapies, for use in human studies. That has largely limited CAR T-cell research to studies of small groups of patients at individual hospitals. To accelerate and speed up that research, NCI has established a program at its labs in Frederick, Maryland, to manufacture CAR T-cell therapies for use in clinical trials at multiple hospitals.
Learn more about the manufacturing initiative in this NCI Cancer Currents blog post: www.cancer.gov/news-events/cancer-currents-blog/2020/car-t-cell-nci-manufacturing-clinical-trials
Learn more about CAR T-cell therapy and other immunotherapies: www.cancer.gov/about-cancer/treatment/types/immunotherapy
Fully-accessible 508-compliant version of this video: smartplayer.captionsync.com/play.php?vid=1613675027jswarz_910560ba3def6881&embed=t
Video of the CliniMACS Prodigy® system courtesy of Miltenyi Biotec.
17 фев 2021
